article

1. Phase 1 dose escalation trial of the selective adenosine A2B antagonist PBF-1129 in patients with metastatic non-small cell lung cancer..  Investigational new drugs.  43:1211-1221. 2025
2. Impact of immune-related and non-immune related hospital admissions on survival of patients with non-small cell lung cancer receiving first-line immunotherapy..  Lung cancer (Amsterdam, Netherlands).  -. 2025
3. Early Changes in Lymphocyte/Monocyte Ratio on Treatment as a Prognostic Marker to Predict Overall Survival in Patients with Advanced Cancer Treated with Immune Checkpoint Inhibitors..  Cancer investigation.  43:717-725. 2025
4. Cognitive-Behavioral Treatment for Breathlessness in Lung Cancer: A Randomized Controlled Trial..  Annals of the American Thoracic Society.  22:1579-1591. 2025
5. Lung Cancer in Older Adults: Screening, Diagnosis, and Treatment..  Clinics in geriatric medicine.  41:553-567. 2025
6. Associations of frailty with survival, hospitalization, functional decline, and toxicity among older adults with advanced non-small cell lung cancer..  The oncologist.  30. 2025
7. Early Acute Kidney Injury and Its Association With Survival in Patients With Metastatic Non-Small-Cell Lung Cancer Treated With Front-Line Immunotherapy-Based Therapies..  Cancer medicine.  14:-. 2025
8. Medically tailored meals in lung cancer care: patient experiences from the NutriCare Clinical Trial..  Journal of cancer survivorship : research and practice.  2025
9. Brief Report: Central Nervous System Metastases After Chemoradiation Followed by Durvalumab for Unresectable Locally Advanced Nonsmall Cell Lung Cancer..  Clinical lung cancer.  26:e566-e571.e2. 2025
10. Comparing the Accuracy of Different Wearable Activity Monitors in Patients With Lung Cancer and Providing Initial Recommendations: Protocol for a Pilot Validation Study..  JMIR research protocols.  -. 2025
11. Impact of an embedded onco-palliative care clinic on urine drug testing in thoracic oncology..  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.  33:-. 2025
12. Adoption of Broad Genomic Profiling in Patients With Cancer..  JAMA oncology.  11:666-668. 2025
13. BPI25-017: A Novel Integrated Classification Schema for Molecular Findings by Potential Clinical Actionability: A Tool for Assessment of Real-World Cancer Care in the Targeted Therapy Era..  Journal of the National Comprehensive Cancer Network : JNCCN.  23. 2025
14. YIA25-002: SyMPLER Palliative Care: Symptom Monitoring Program Linked to Electronic Referrals to Palliative Care..  Journal of the National Comprehensive Cancer Network : JNCCN.  23. 2025
15. Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2024.3..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  43:e2-e16. 2025
16. Evaluating the effect of immune checkpoint inhibitor treatment on chronic obstructive pulmonary disease in lung cancer patients..  Oncoimmunology.  14:-. 2025
17. The Fifth Annual Symposium of the Midwest Aging Consortium..  The journals of gerontology. Series A, Biological sciences and medical sciences.  80. 2025
18. Strength of evidence underlying the CMS-FDA parallel review of comprehensive genomic profiling tests in the cancer setting..  Journal of the National Cancer Institute.  117:144-151. 2025
19. Analysis of a Pilot Study Delivering Cancer Survivorship Education to Community Healthcare Professionals Utilizing the Project ECHO Model..  Journal of CME.  13:-. 2024
20. Lung cancer patients' illness perceptions: Prognostic for psychological and physical health trajectories..  Health psychology : official journal of the Division of Health Psychology, American Psychological Association.  43:913-923. 2024
21. Function, cognition, and quality of life among older adults with lung cancer who live alone: A prospective cohort study..  Journal of geriatric oncology.  15:-. 2024
22. Improved survival for patients with lung cancer treated with perioperative immunotherapy..  Lancet (London, England).  404:1176-1178. 2024
23. Functional resilience and overall survival in adults treated for advanced non-small-cell lung cancer..  Lung cancer (Amsterdam, Netherlands).  -. 2024
24. A video intervention to improve patient understanding of tumor genomic testing in patients with cancer..  Cancer medicine.  13:-. 2024
25. Resiliency among older adults receiving lung cancer treatment (ROAR-LCT): A novel supportive care intervention for older adults with advanced lung cancer..  Journal of geriatric oncology.  15:-. 2024
26. Practical Insights From Integrating Financial Hardship Screening at a Comprehensive Cancer Center..  Journal of the American College of Radiology : JACR.  21:1398-1401. 2024
27. A theoretical explanation for how a nutrition counseling and medically tailored meal delivery program benefitted participants living with lung cancer..  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.  32:-. 2024
28. The FITNESS study: longitudinal geriatric assessment, treatment toxicity, and biospecimen collection to assess functional disability among older adults with lung cancer..  Frontiers in aging.  -. 2024
29. Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study..  Cancer letters.  -. 2024
30. Survivorship in Advanced Lung Cancer: Understanding a New Landscape and Opportunities..  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.  44:-. 2024
31. Trajectories of Health Care Contact Days for Patients With Stage IV Non-Small Cell Lung Cancer..  JAMA network open.  7:-. 2024
32. Lung cancer screening use among screening-eligible adults with disabilities..  Journal of the American Geriatrics Society.  72:1155-1165. 2024
33. How a Medically Tailored Meal Intervention with Intensive Nutrition Counseling Created Active Coping with Behavior Change for Vulnerable Patients with Lung Cancer..  Research square.  2024
34. A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients with Cancer..  medRxiv : the preprint server for health sciences.  2023
35. A cognitive-behavioral model of dyspnea: Qualitative interviews with individuals with advanced lung cancer..  Palliative & supportive care.  21:1070-1077. 2023
36. Disparities in outcomes between Black and White patients in North America with thoracic malignancies and COVID-19 infection (TERAVOLT)..  Lung cancer (Amsterdam, Netherlands).  -. 2023
37. Association Between Pretreatment Chest Imaging and Immune Checkpoint Inhibitor Pneumonitis Among Patients With Lung Cancer..  Journal of the National Comprehensive Cancer Network : JNCCN.  21:1164-1171.e5. 2023
38. Changes in physical function in older women with endometrial cancer with or without adjuvant therapy..  Journal of cancer survivorship : research and practice.  19:206-215. 2023
39. Risk Factors for Immune Checkpoint Inhibitor Immunotherapy Toxicity Among Older Adults with Cancer..  The oncologist.  28:e625-e632. 2023
40. Net Clinical Benefit as Measure of Treatment Benefit Among Older Adults With Advanced Incurable Non-Small Cell Lung Cancer-Reply..  JAMA oncology.  9:1154-1155. 2023
41. "Celebrating Resilience": A review of abstracts on functional resilience at the International Society of Geriatric Oncology 2022 annual meeting..  Journal of geriatric oncology.  14:-. 2023
42. Cancer rarely travels alone: Addressing the accumulation of risk and early mortality for older adults with advanced lung cancer..  Journal of geriatric oncology.  15:-. 2023
43. Improving Access to Early Palliative Care Delivery for Patients With an Advanced Thoracic Malignancy Through an Embedded Oncopalliative Clinic Model..  JCO oncology practice.  19:777-785. 2023
44. Correction: Association between pre‑treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis..  Cancer immunology, immunotherapy : CII.  72:-. 2023
45. Clinical outcomes of immunotherapy continued beyond radiographic disease progression in older adult patients with advanced non‑small cell lung cancer..  Oncology letters.  25:-. 2023
46. Association Between Age and Survival Trends in Advanced Non-Small Cell Lung Cancer After Adoption of Immunotherapy..  JAMA oncology.  9:334-341. 2023
47. Cancer-related Fatigue in Lung Cancer: A Research Agenda: An Official American Thoracic Society Research Statement..  American journal of respiratory and critical care medicine.  207:e6-e28. 2023
48. Estimating Cancer Treatment Tolerability for Older Adults With Advanced Cancer-The Holy Grail..  JAMA network open.  6:-. 2023
49. Depression in association with neutrophil-to-lymphocyte, platelet-to-lymphocyte, and advanced lung cancer inflammation index biomarkers predicting lung cancer survival..  PloS one.  18:-. 2023
50. Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy..  Cancer immunology, immunotherapy : CII.  72:2067-2074. 2023
51. Feasibility of an embedded palliative care clinic model for patients with an advanced thoracic malignancy..  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.  31:-. 2023
52. Association of medical comorbidities and cardiovascular disease with toxicity and survival among patients receiving checkpoint inhibitor immunotherapy..  Cancer immunology, immunotherapy : CII.  72:2005-2013. 2023
53. Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis..  Cancer immunology, immunotherapy : CII.  72:1727-1735. 2023
54. Barriers to and recommendations for integrating the age-friendly 4-Ms framework into electronic health records..  Journal of the American Geriatrics Society.  71:1573-1579. 2022
55. End-of-life care trajectories among older adults with lung cancer..  Journal of geriatric oncology.  14:-. 2022
56. Patient Understanding of Tumor Genomic Testing: A Quality Improvement Effort..  JCO oncology practice.  19:e8-e14. 2022
57. Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival..  Journal of cancer research and clinical oncology.  149:2235-2242. 2022
58. Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors..  Biomedicines.  10. 2022
59. Change in four measures of physical function among older adults during lung cancer treatment: A mixed methods cohort study..  Journal of geriatric oncology.  14:-. 2022
60. Risk factors and predictors of immune-related adverse events: implications for patients with non-small cell lung cancer..  Expert review of anticancer therapy.  22:861-874. 2022
61. Association of Allostatic Load With Overall Mortality Among Patients With Metastatic Non-Small Cell Lung Cancer..  JAMA network open.  5:-. 2022
62. Characterization of older adults with cancer seeking acute emergency department care: A prospective observational study..  Journal of geriatric oncology.  13:943-951. 2022
63. Illness perception profiles and psychological and physical symptoms in newly diagnosed advanced non-small cell lung cancer..  Health psychology : official journal of the Division of Health Psychology, American Psychological Association.  41:379-388. 2022
64. Coronavirus Disease 2019 Outcomes, Patient Vaccination Status, and Cancer-Related Delays During the Omicron Wave: A Brief Report From the TERAVOLT Analysis..  JTO clinical and research reports.  3:-. 2022
65. Functional Trajectories and Resilience Among Adults With Advanced Lung Cancer..  JTO clinical and research reports.  3:-. 2022
66. Risk Factors and Biomarkers for Immune-Related Adverse Events: A Practical Guide to Identifying High-Risk Patients and Rechallenging Immune Checkpoint Inhibitors..  Frontiers in immunology.  -. 2022
67. A Geriatric Assessment Intervention to Reduce Treatment Toxicity Among Older Adults With Advanced Lung Cancer: A Subgroup Analysis From a Cluster Randomized Controlled Trial..  Frontiers in oncology.  -. 2022
68. Aggressive End-of-Life Care in the Veterans Health Administration versus Fee-for-Service Medicare among Patients with Advanced Lung Cancer..  Journal of palliative medicine.  25:932-939. 2022
69. Impact of an Embedded Palliative Care Clinic on Healthcare Utilization for Patients With a New Thoracic Malignancy..  Frontiers in oncology.  -. 2022
70. Polypharmacy in older adults with cancer undergoing radiotherapy: A review..  Journal of geriatric oncology.  13:778-783. 2022
71. A Definitive Prognostication System for Patients With Thoracic Malignancies Diagnosed With Coronavirus Disease 2019: An Update From the TERAVOLT Registry..  Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.  17:661-674. 2022
72. Cancer Treatment During COVID-19: Resilience of Individuals With Advanced Non-Small Cell Lung Cancer Versus Community Controls..  Journal of the National Comprehensive Cancer Network : JNCCN.  20:118-125. 2022
73. Clinical Effectiveness and Safety of Anti-PD-(L)1 Therapy Among Older Adults With Advanced Non-Small Cell Lung Cancer..  Clinical lung cancer.  23:236-243. 2022
74. Psychological Symptom Trajectories and Non-Small Cell Lung Cancer Survival: A Joint Model Analysis..  Psychosomatic medicine.  84:215-223. 2022
75. Integration of a Geriatric Assessment With Intervention in the Care of Older Adults With Hematologic Malignancies..  Frontiers in oncology.  -. 2021
76. Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study..  JAMA oncology.  7:1856-1861. 2021
77. Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers..  JAMA network open.  4:-. 2021
78. Immune checkpoint inhibitor-related thrombocytopenia: incidence, risk factors and effect on survival..  Cancer immunology, immunotherapy : CII.  71:1157-1165. 2021
79. Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study..  Journal of the American Geriatrics Society.  70:136-149. 2021
80. Feasibility of implementing an exercise intervention in older adults with hematologic malignancy..  Journal of geriatric oncology.  13:234-240. 2021
81. Harmonized Outcome Measures for Use in Non-Small Cell Lung Cancer Patient Registries and Clinical Practice..  Journal of the National Comprehensive Cancer Network : JNCCN.  2021
82. Immunotherapy in Older Adults With Cancer..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  39:2115-2127. 2021
83. Substance Abuse Risk and Medication Monitoring in Patients with Advanced Lung Cancer Receiving Palliative Care..  Journal of pain & palliative care pharmacotherapy.  35:91-99. 2021
84. Too Many Appointments: Assessing Provider and Nursing Perception of Barriers to Referral for Outpatient Palliative Care..  Palliative medicine reports.  2:137-145. 2021
85. Functional Disability Among Older Versus Younger Adults With Advanced Non-Small-Cell Lung Cancer..  JCO oncology practice.  17:e848-e858. 2021
86. Bone Metastases, Skeletal-Related Events, and Survival in Patients With Metastatic Non-Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors..  Journal of the National Comprehensive Cancer Network : JNCCN.  19:915-921. 2021
87. Characteristics Associated With Functional Changes During Systemic Cancer Treatments: A Systematic Review Focused on Older Adults..  Journal of the National Comprehensive Cancer Network : JNCCN.  19:1055-1062. 2021
88. Care Disparities Across the Health Care Continuum for Older Adults: Lessons From Multidisciplinary Perspectives..  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.  1-10. 2021
89. Line of therapy and patient preferences regarding lung cancer treatment: a discrete-choice experiment..  Current medical research and opinion.  37:643-653. 2021
90. Comparative assessment of manual chart review and ICD claims data in evaluating immunotherapy-related adverse events..  Cancer immunology, immunotherapy : CII.  70:2761-2769. 2021
91. Checkpoint inhibitor immunotherapy toxicity and overall survival among older adults with advanced cancer..  Journal of geriatric oncology.  12:813-819. 2021
92. The aging microbiome and response to immunotherapy: Considerations for the treatment of older adults with cancer..  Journal of geriatric oncology.  12:985-989. 2021
93. End-of-life patterns of symptom management and cancer-directed care among Medicare beneficiaries with lung cancer: a claims-based analysis..  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.  29:3921-3932. 2021
94. Brief report: inhaled corticosteroid use and the risk of checkpoint inhibitor pneumonitis in patients with advanced cancer..  Cancer immunology, immunotherapy : CII.  69:2403-2408. 2020
95. Integration of geriatric assessment into routine oncologic care and advances in geriatric oncology: A young International Society of Geriatric Oncology Report of the 2020 American Society of Clinical Oncology (ASCO) annual meeting..  Journal of geriatric oncology.  11:1324-1328. 2020
96. Adoption of Immune Checkpoint Inhibitors and Patterns of Care at the End of Life..  JCO oncology practice.  16:e1355-e1370. 2020
97. Patterns of Opioid Prescribing among Medicare Advantage Beneficiaries with Pain and Cardiopulmonary Conditions..  Journal of palliative medicine.  24:195-204. 2020
98. Implementing a multidisciplinary approach for older adults with Cancer: geriatric oncology in practice..  BMC geriatrics.  20:-. 2020
99. Analysis of Patient Preferences in Lung Cancer - Estimating Acceptable Tradeoffs Between Treatment Benefit and Side Effects..  Patient preference and adherence.  927-937. 2020
100. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer..  JAMA network open.  3:-. 2020
101. Multidisciplinary telemedicine and the importance of being seen..  Journal of geriatric oncology.  11:1349-1351. 2020
102. Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications..  BMC cancer.  20:-. 2020
103. Severe functional limitation due to pain & emotional distress and subsequent receipt of prescription medications among older adults with cancer..  Journal of geriatric oncology.  11:960-968. 2020
104. Concurrent Hospice Care and Cancer-Directed Treatment for Advanced Lung Cancer and Receipt of Aggressive Care at the End of Life in the Veteran's Health Administration..  Journal of palliative medicine.  23:1038-1044. 2020
105. Patterns of Symptom Management Medication Receipt at End-of-Life Among Medicare Beneficiaries With Lung Cancer..  Journal of pain and symptom management.  59:767-777.e1. 2019
106. Newly diagnosed patients with advanced non-small cell lung cancer: A clinical description of those with moderate to severe depressive symptoms..  Lung cancer (Amsterdam, Netherlands).  195-204. 2019
107. Patterns of pain medication use associated with reported pain interference in older adults with and without cancer..  Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer.  28:3061-3072. 2019
108. A story of connection: A tribute to Arti Hurria, MD..  Journal of geriatric oncology.  11:164-165. 2019
109. Change in neutrophil to lymphocyte ratio during immunotherapy treatment is a non-linear predictor of patient outcomes in advanced cancers..  Journal of cancer research and clinical oncology.  145:2541-2546. 2019
110. Geriatric oncology research at the 2019 American Geriatrics Society (AGS) annual meeting: Joint perspectives from the Young International Society of Geriatric Oncology (SIOG) and AGS Cancer and Aging Special Interest Group..  Journal of geriatric oncology.  10:994-997. 2019
111. Treatment-Related Complications of Systemic Therapy and Radiotherapy..  JAMA oncology.  5:1028-1035. 2019
112. Mentoring pearls of wisdom: Lessons learned by mentees of Arti Hurria, MD..  Journal of geriatric oncology.  11:335-337. 2019
113. Value-Added Decisions in Oncology..  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.  122-131. 2019
114. Disparities in broad-based genomic sequencing for patients with advanced non-small cell lung cancer..  Journal of geriatric oncology.  10:669-672. 2019
115. Prioritization of Patient-Reported Outcomes by Women With Metastatic Breast Cancer..  JCO clinical cancer informatics.  1-3. 2019
116. Addressing New Diagnostic and Treatment Challenges Associated With a New Age of Cancer Treatment..  Annals of emergency medicine.  73:88-90. 2018
117. Speed of Adoption of Immune Checkpoint Inhibitors of Programmed Cell Death 1 Protein and Comparison of Patient Ages in Clinical Practice vs Pivotal Clinical Trials..  JAMA oncology.  4:-. 2018
118. Association of Broad-Based Genomic Sequencing With Survival Among Patients With Advanced Non-Small Cell Lung Cancer in the Community Oncology Setting..  JAMA.  320:469-477. 2018
119. Functional trajectories before and after a new cancer diagnosis among community-dwelling older adults..  Journal of geriatric oncology.  10:60-67. 2018
120. Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults..  Current oncology reports.  19:-. 2017
121. Information Needs of Older Women With Early-Stage Breast Cancer When Making Radiation Therapy Decisions..  International journal of radiation oncology, biology, physics.  98:733-740. 2017
122. Caring for the Older Population With Advanced Lung Cancer..  American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.  587-596. 2017
123. Treatment Burden of Medicare Beneficiaries With Stage I Non-Small-Cell Lung Cancer..  Journal of oncology practice.  13:e98-e107. 2016
124. Gaps in nutritional research among older adults with cancer..  Journal of geriatric oncology.  7:281-92. 2016
125. Designing exercise clinical trials for older adults with cancer: Recommendations from 2015 Cancer and Aging Research Group NCI U13 Meeting..  Journal of geriatric oncology.  7:293-304. 2016
126. Optimizing Treatment Risk and Benefit for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Right Treatment for the Right Patient..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  34:1438-42. 2016
127. The Treatment of Advanced Lung Cancer in the Elderly: The Role of a Comprehensive Geriatric Assessment and Doublet Chemotherapy..  Cancer journal (Sudbury, Mass.).  21:392-7. 2015
128. Reply to L.W. Cuttino et al..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  31:2227-9. 2013
129. A new approach to understanding racial disparities in prostate cancer treatment..  Journal of geriatric oncology.  4:1-8. 2013
130. Patterns of use and short-term complications of breast brachytherapy in the national medicare population from 2008-2009..  Journal of clinical oncology : official journal of the American Society of Clinical Oncology.  30:4302-7. 2012
131. The relationship between clinical benefit and receipt of curative therapy for prostate cancer..  Archives of internal medicine.  172:362-3. 2012